LOR-S03

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameLOR-S03
Drug Alias NameCDX-527
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCD27 antigen inhibitorsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1CD27 antigen
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelldex Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesCelldex Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A